4Michael AE, Webley GE. Prostaglandin F2 alpha astimulates cAMP phosphodiesterase via protein kinase C in cultured human granulosa cells[ J]. Mol cell Endocrinol,1999,82(2 -3) :207 -214. 被引量：1
5Maurice DH, Palmer D, Tilley DG et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system[ J]. Mol Pharmaco1,2003,64( 3 ) :533 - 546. 被引量：1
6Okada S, Ohshima K, Mori M. Phosphodiesterase 3 ( PDE3 ) attenuates insulin secretion from the human pancreas: a specific PDE3 inhibitor improves insulin secretion in type Ⅱ diabetes mellitus [ J ]. Endoer J, 2002,49(5 ) :581 - 582. 被引量：1
6Germain N, Bertin B, Legendre A, et al. Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea - pigs [ J ]. Eur Respir J,1998,212(12) : 1334- 1339. 被引量：1
7Salehi A, Ekelund M, Henningsson R, et al. Total parenteral nutrition modulates hormone release by sthnulating expression and acitivity of inducible nitric oxide synthase in rat pancreatic islets[J]. Endocrine, 2001,16(2): 97-104. 被引量：1
8Shafiee- Nick R, Pyne NJ, Furman BL. Effects of type-specific phosphodiesterase inhibitom on insulin secretion from rat isolated islets[J]. Diabetic Med, 1993,10(Suppl 1) : S48-S52. 被引量：1
9Mei J, Landstrom TR, C Holm, et al. C(2) - ceramide influences the expression and insulin- mediated regulation cyclic nudeotide phosphodiesterase 3B and lipolysis in 3T3- L1 adipocytes[J]. Diabetes, 2002, 51(3): 631-637. 被引量：1
10Parker JC, Vanvolkenburg MA, Ketchum RJ, et al. Cyclic AMP phosphodiesters of human and rat islets of langerhans:contributiom of types Ⅲ and Ⅳ to the modulation of insulin secretion[J]. Biochem Biophys Res Commun, 1997, 217(5) : 916- 923. 被引量：1
3Lugnier C.Cyclic nucleotide phosphodiesterase (PDE) superfamily:a new target for the development of specific therapeutic agents[J].Pharmacolo Ther,2006,109(3):366-398. 被引量：1
4Jeon YH,Heo YS,Kim CM,et al.Phosphodiesterase:overview of protein structures,potential therapeutic applications and recent progress in drug development[J].Cell Mol Life Sci,2005,62(11):1198-1220. 被引量：1
5Omori K,Kotera J.Overview of PDEs and their regulation[J].Circ Res,2007,100(3):309-327. 被引量：1
6Giembycz MA,Field SK.Roflumilast:first phosphodiesterase 4 inhibitor approved for treatment of COPD[J].Drug Des Devel Ther,2010,4:147-158. 被引量：1
7Hatzelmann A,Morcillo EJ,Lungarella G,et al.The preclinical pharmacology of roflumilast--a selective,oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease[J].Pulm Pharmacol Ther,2010,23(4):235-256. 被引量：1
8van den Berge M,ten Hacken NH,et al.Small airway disease in asthma and COPD:clinical implications[J].Chest,2011,139(2):412-423. 被引量：1
9Kroegel C,Wirtz H.History of guidelines for the diagnosis and management of asthma:from opinion to control[J].Drugs,2009,69(9):1189-1204. 被引量：1
10Bateman ED,Hurd SS,Barnes PJ,et al.Global strategy for asthma management and prevention:GINA executive summary[J].Eur Respir J,2008,31(1):143-178. 被引量：1
